You are using an old and unsupported browser. Most core functionality will not work. Please upgrade to a supported browser - Google Chrome

GP20 | RACGP
#GP20Connect
GP20 | RACGP
Home
Seqirus - A CSL Company

Seqirus - A CSL Company

Melbourne, Australia

About Seqirus - A CSL Company

Seqirus has public health protection at its core, reflecting the promise of our parent company, CSL Limited, founded in 1916 to save lives and protect the health of people. Together with our partners on the front line, we have served Australia’s healthcare needs for over a century and we operate Australia’s only local manufacturing facility for seasonal and pandemic influenza vaccine. As the only vaccine company with a singular global focus on influenza, our vision is a world protected from influenza. 
 

Exhibition competition code word: VACCINE

Resources

Information about a new influenza vaccine
Flucelvax Quad Product Information
At risk patient information
Q Fever information fro General Practitioners
A list of the vaccines in the Seqirus portfolio
This 1-hour accredited program will help GPs understand the significant burden of shingles in Australia, including the risks of post-herpetic neuralgia (PHN) and stroke, and the rationale for vaccination. The program will support clinicians in proactively identifying individuals aged ≥50 years who may benefit from shingles vaccination, such as those with diabetes, and assist them in managing shingles vaccination in the context of immunosuppressive therapies. Featuring three cases studies and expert video questions, this program highlights the importance of identifying patients who will benefit from shingles vaccination. Sponsor statement : This educational activity was developed by MdBriefCase at the request, and with funding from Seqirus. Please see QR code attached to access CPD Program